Biological Information | |
---|---|
Background Information: | N-terminal 6His-tagged recombinant, human Abl, amino acids 27-end containing the Y253F mutation. The Abl tyrosine kinase inhibitor STI571 is an effective therapy for stable-phase chronic myeloid leukemia patients. Many patients responding to STI571 later relapse due to a reactivation of Bcr-Abl activity. In certain cases this appears to correlate with the presence of the Y253F mutation, which confers resistance to drug binding (Shah et al., (2002), Cancer Cell 2, 117-125). |
Target Class: | Kinase |
Accession Number: | U07563 |
Target Name: | Abl |
Target Aliases: | ABL1, JTK7, ABL, p150, vABL, cABL, bcr/abl |
Target Species: | Human |
Usage | |
Product Type: | Enzymes |
Application: | Drug Discovery & Development |
Storage Conditions: | 6 months at -70°C |
Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
Abl (Y253F), active
Datasheets
14-759x Datasheet
View Document